Tivozanib Approval Status
- FDA approved: No
- Generic name: tivozanib
- Company: AVEO Oncology and Astellas Pharma Inc.
- Treatment for: Renal Cell Carcinoma
Tivozanib is an investigational tyrosine kinase inhibitor for the treatment of advanced renal cell carcinoma.
In June 2013, AVEO Oncology announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for tivozanib had not been approved.
Development Status and FDA Approval Process for tivozanib
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.